A need for biomarkers of NRF2 inhibition has been articulated across cancer types, and our data suggest that HO-1 or downstream redox changes such as ROS levels or GSH/GSSG ratios may serve this purpose in AML. The gene discussed is HMOX1; the disease is acute myeloid leukemia.